Pairidex Secures Lead Investment from BioGenerator Ventures for the Launch of New Highly Sensitive MRD Test for LeukemiaReducing Uncertainty in the Care and Treatment of Blood Cancer
ST. LOUIS, MO, UNITED STATES, February 23, 2026 /EINPresswire.com/ -- Pairidex, an emerging leader in leukemia detection, today announced a lead investment from BioGenerator Ventures that will enable the launch of FusionMRD™, a new personalized, RNA-based assay for the monitoring of measurable residual disease (MRD) in fusion-driven hematological malignancies. FusionMRD™ is commercially available as a laboratory developed test (LDT) for...
Pairidex Featured in St. Louis Business Journal
PAIRIDEX Headquarters: St. Louis (BioGenerator Labs in the Cortex district) What it does: Pairidex is developing a novel droplet digital PCR platform for more accurate, personalized monitoring of blood cancer. The latest: Pairidex established operations just over one year ago. Since then, Pairidex has closed an oversubscribed pre-seed round, licensed the necessary IP from WashU, established a CLIA-certified laboratory, and completed its first commercial sale. Why you should watch it: Our mission is to...
Innovators Hour: Interview with Andrew Young & Allyson Mayer of Pairidex
Jim McCarter, Senior Managing Director of BioGenerator Ventures, sits down with Andrew Young, MD, PhD, of Pairidex and WashU, and Allyson Mayer, PhD, of Pairidex and BioGenerator Ventures. Pairidex is the developer of a droplet digital PCR assay designed to enable accurate detection of gene fusions in blood cancer. Innovators Hour, hosted by BioGenerator, the start-up arm of BioSTL, spotlights...
We are thrilled to announce the appointment of Paul Kortschak as the new Chief Executive Officer of Pairidex
Paul brings to Pairidex over 20 years of executive leadership experience across the biotech and clinical industries, with a proven track record of driving innovation, scaling organizations, and building high-performing teams. Most recently, he served as CEO at NX Prenatal. Pairidex continues to grow and evolve in developing droplet digital PCR assays designed to enable accurate detection of gene fusions...
Pairidex Welcomes Eric Green, M.D., Ph.D. as an Advisor
Pairidex welcomes Eric Green, M.D., Ph.D., former director of the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health (NIH) from 2009 to 2025 as an Advisor. Dr. Green guided work aimed at improving our understanding of human genetics and using those findings to help develop treatments for genetic diseases. Dr. Green will provide valuable input as...
Unlocking Potential: How Science Coach and BioSTL Are Shaping the Future of STEM EducationFrom Small-Town Roots to Bioscience Innovation
From Small-Town Roots to Bioscience Innovation When all the pieces fall into place, miraculous things happen. Hannah Davis is living proof. At 23, she’s a promising scientist and Research Associate at Pairidex, Inc., a company focused on pioneering blood cancer detection methods—potentially life-saving innovations for leukemia patients. Her journey, from a small-town high school to cutting-edge biomedical research, represents the full realization of BioSTL’s vision to change the world...
Pairidex announces new clinical test to monitor leukemia patient therapeutic responsePairidex today announced the launch of FusionMRD™, for the monitoring of measurable residual disease (MRD) in fusion-driven hematological malignancies.
ST. LOUIS, MO, UNITED STATES, February 23, 2026 /EINPresswire.com/ -- Pairidex, an emerging leader in leukemia detection, today announced the launch of FusionMRD™, a new personalized, RNA-based assay for the monitoring of measurable residual disease (MRD) in fusion-driven hematological malignancies that is now available as a laboratory-developed test (LDT) in the United States. FusionMRD™ is commercially available for personalized gene...
Technical Advance: Droplet Digital PCR for Oncogenic KMT2A Fusion
Acute myeloid leukemia (AML) is an aggressive blood cancer diagnosed in approximately 120,000 individuals worldwide each year. During treatment for AML, detecting residual disease is essential for prognostication and treatment decision-making. Currently, methods for detecting residual AML are limited to identifying approximately 1:100 to 1:1000 leukemic cells (morphology and DNA sequencing) or are difficult to implement...
Connect with us
Discover how our innovative solutions can transform your approach to cancer detection and monitoring. We’d love to show you what we can do.